VERVE-201

N/A

Report date: 2025/12/08 17:13:52

Base Information

Drug NameVERVE-201
Drug Alias NameANGPTL3 targeted gene editing therapy(Verve Therapeutics)ANGPTL3 Editor (VERVE-201)VERVE-201
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR
Mechanisms of ActionGene expression modulatorsAngiopoietin like 3 inhibitors
TargetsAngiopoietin like 3
Therapy Area/IndicationsHomozygous familial hypercholesterolemiaHypertriglyceridemiaHypercholesterolemia +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSouth Africa +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBroad InstituteHarvard University
China Registration ClassN/A

Develop Information

Active CompaniesVerve Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHomozygous familial hypercholesterolemiaHypertriglyceridemiaHypercholesterolemia +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A